JP2022051745A5 - - Google Patents

Download PDF

Info

Publication number
JP2022051745A5
JP2022051745A5 JP2022001586A JP2022001586A JP2022051745A5 JP 2022051745 A5 JP2022051745 A5 JP 2022051745A5 JP 2022001586 A JP2022001586 A JP 2022001586A JP 2022001586 A JP2022001586 A JP 2022001586A JP 2022051745 A5 JP2022051745 A5 JP 2022051745A5
Authority
JP
Japan
Prior art keywords
solid composition
use according
substituted glycine
group
additional
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022001586A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022051745A (ja
Filing date
Publication date
Priority claimed from US15/646,034 external-priority patent/US10226442B2/en
Application filed filed Critical
Publication of JP2022051745A publication Critical patent/JP2022051745A/ja
Publication of JP2022051745A5 publication Critical patent/JP2022051745A5/ja
Pending legal-status Critical Current

Links

JP2022001586A 2017-07-10 2022-01-07 N-置換グリシン化合物のリチウム塩及びその使用 Pending JP2022051745A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US15/646,034 2017-07-10
US15/646,034 US10226442B2 (en) 2017-07-10 2017-07-10 Lithium salts of N-substituted glycine compounds and uses thereof
JP2020500693A JP7049001B2 (ja) 2017-07-10 2018-07-10 N-置換グリシン化合物のリチウム塩及びその使用
PCT/US2018/041420 WO2019014207A1 (en) 2017-07-10 2018-07-10 LITHIUM SALTS OF N-SUBSTITUTED GLYCIN COMPOUNDS AND USES THEREOF

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2020500693A Division JP7049001B2 (ja) 2017-07-10 2018-07-10 N-置換グリシン化合物のリチウム塩及びその使用

Publications (2)

Publication Number Publication Date
JP2022051745A JP2022051745A (ja) 2022-04-01
JP2022051745A5 true JP2022051745A5 (enExample) 2022-08-29

Family

ID=64903694

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020500693A Active JP7049001B2 (ja) 2017-07-10 2018-07-10 N-置換グリシン化合物のリチウム塩及びその使用
JP2022001586A Pending JP2022051745A (ja) 2017-07-10 2022-01-07 N-置換グリシン化合物のリチウム塩及びその使用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2020500693A Active JP7049001B2 (ja) 2017-07-10 2018-07-10 N-置換グリシン化合物のリチウム塩及びその使用

Country Status (10)

Country Link
US (3) US10226442B2 (enExample)
EP (1) EP3651759A4 (enExample)
JP (2) JP7049001B2 (enExample)
KR (1) KR102645410B1 (enExample)
CN (1) CN110891562B (enExample)
CA (1) CA3069669A1 (enExample)
IL (1) IL271781B2 (enExample)
RU (1) RU2020105865A (enExample)
TW (2) TWI735790B (enExample)
WO (1) WO2019014207A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10226442B2 (en) * 2017-07-10 2019-03-12 Syneurx International (Taiwan) Corp. Lithium salts of N-substituted glycine compounds and uses thereof
CA3107566A1 (en) * 2017-08-07 2019-02-14 Enantia, S.L. A cocrystal of 2-[(1r,6r)-6-isopropenyl-3-methylcyclohex-2-en-1-yl]-5-pentylbenzene-1,3-diol
IT202000019303A1 (it) * 2020-08-05 2022-02-05 Univ Degli Studi Di Brescia Analoghi strutturali del metilfenidato come agenti disease-modifying della malattia di parkinson

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2796349A (en) 1955-04-21 1957-06-18 Gen Foods Corp Food product
GB8311804D0 (en) 1983-04-29 1983-06-02 Merrell Toraude & Co Treatment of seizure disorders and pharmaceutical compositions
DE69936848T2 (de) * 1998-04-14 2008-05-15 The General Hospital Corp., Boston Verwendung von d-serin oder d-alanin zur behandlung von schizophrenie
TW555757B (en) * 1998-07-31 2003-10-01 Akzo Nobel Nv Aminomethylcarboxylic acid derivatives
WO2006050531A2 (en) * 2004-11-05 2006-05-11 The Ohio State University Research Foundation Membranes, methods of making membranes, and methods of separating gases using membranes
US7446096B2 (en) * 2005-12-19 2008-11-04 Industrial Technology Research Institute Glutathione based delivery system
US8604080B2 (en) * 2007-02-14 2013-12-10 W. Louis Cleveland High dose glycine as a treatment for obsessive-compulsive disorder and obsessive compulsive spectrum disorders
JP5623076B2 (ja) 2007-07-20 2014-11-12 株式会社コーセー ベシクル組成物、及び皮膚外用剤
WO2009018368A1 (en) * 2007-07-30 2009-02-05 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Combination treatment of nmda (n-methyl-d-aspartate)-enhancer, glycine transporter inhibitor, d-amino acid oxidase inhibitor (daaoi) for neuropsychiatric disorders
WO2012024293A2 (en) 2010-08-16 2012-02-23 Genomind, Llc Medical foods for the treatment of developmentally-based neuropsychiatric disorders via modulation of brain glycine and glutathione pathways
US10130708B2 (en) * 2011-03-24 2018-11-20 University Of South Florida Lithium cocrystal compositions
WO2016002774A1 (ja) * 2014-07-02 2016-01-07 セントラル硝子株式会社 イオン性錯体、非水電解液電池用電解液、非水電解液電池及びイオン性錯体の合成法
PE20170470A1 (es) 2014-07-03 2017-05-14 Nan Global Llc Metodos y composiciones para tratar la obesidad, prevenir el aumento de peso, promover la perdidad de peso, promover el adelgazamiento o tratar o prevenir el desarrollo de la diabetes
US10226442B2 (en) * 2017-07-10 2019-03-12 Syneurx International (Taiwan) Corp. Lithium salts of N-substituted glycine compounds and uses thereof

Similar Documents

Publication Publication Date Title
JP2022051745A5 (enExample)
US20240262840A1 (en) Heterocyclic flavone derivatives, compositions, and methods related thereto
JP2019515891A5 (enExample)
TWI638654B (zh) 用以治療中樞神經系統疾病之包含苯甲酸鹽化合物及鞣酸的組合物
JP2015516395A5 (enExample)
JP2015535290A (ja) 7,8−ジヒドロキシフラボンおよび7,8−置換フラボン誘導体、組成物、およびそれらに関連する方法
JP2004534066A5 (enExample)
CA2448025A1 (en) Use of cox-2 inhibitors for the treatment of schizophrenia, delusional disorders, affective disorders, autism or tic disorders
JP2019147843A (ja) 吃音を治療するための融合ベンズアゼピン
JP2025084754A5 (enExample)
AU758181B2 (en) Therapeutic agents
RU2020125170A (ru) Композиции и способы улучшения биодоступности 5-гидрокситриптофана
AU2007260631B2 (en) Treating psychological conditions using muscarinic receptor M1 antagonists
RU2020105865A (ru) Литиевые соли n-замещенных глициновых соединений и их применение
TWI455712B (zh) 增強神經藥方療效的山梨酸與苯甲酸及其衍生物
JPWO2020070706A5 (enExample)
JP2007534747A (ja) 肥満、肥満に関連する障害、および他の障害の治療/管理におけるプレグナン配糖体の使用
JP5371762B2 (ja) ムスカリン性受容体m1拮抗薬による肥満の処置
AU3757800A (en) Method of controlling weight gain associated with therapeutic drugs
JP2007505156A5 (enExample)
CN102600277A (zh) 一种含有巴戟天提取物的药用组合物
Puri Drugs in psychiatry
CN101472476B (zh) 毒蕈碱型受体m1拮抗剂在制备治疗肥胖症的药物中的应用
RU2455981C2 (ru) Лечение ожирения антагонистами мускаринового рецептора м1
JPWO2019148087A5 (enExample)